• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. Apr 2003; 62(4): 332–336.
PMCID: PMC1754496

Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index

Abstract

Background: Cartilage normally has a slow turnover but in arthritis increased metabolism results in degradation of the tissue.

Objective: To assess cartilage turnover in a sample of the general population by an assay measuring cartilage derived urinary collagen type II (CTX-II) C-telopeptide degradation products.

Methods: CTX-II concentrations were measured in urine samples from 615 healthy men and women aged 20–87 years, and the influence of age, sex, menopause, hormone replacement therapy (HRT), and body mass index (BMI) was assessed.

Results: CTX-II concentrations showed age dependent variations, with notable differences between men and women. Mean (SD) CTX-II concentration in postmenopausal women (220 (118) ng/mmol, n=25) was significantly higher than in an age matched group of premenopausal women (112 (79) ng/mmol, n=26, p<0.001). CTX-II concentration in women using HRT (118 (57) ng/mmol, n=50) was significantly lower than in an age and BMI matched group of women not receiving HRT (215 (99) ng/mmol, n=50, p<0.001). In subjects with a BMI ≥25 kg/m2, CTX-II concentrations were significantly higher than in those with a BMI <25 kg/m2 (185 (114) v 148 (91) ng/mmol, p<0.001).

Conclusions: Cartilage turnover, as assessed by measuring urinary degradation products of CTX-II varies considerably with age, and significant differences between CTX-II levels in men and women as well as in pre- and postmenopausal women are found. Further studies are required to validate the marker for assessing cartilage degradation in arthritis.

Full Text

The Full Text of this article is available as a PDF (176K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Elders MJ. The increasing impact of arthritis on public health. J Rheumatol Suppl. 2000 Oct;60:6–8. [PubMed]
  • Boini S, Guillemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis. 2001 Sep;60(9):817–827. [PMC free article] [PubMed]
  • Vignon E, Garnero P, Delmas P, Avouac B, Bettica P, Boers M, Ehrich E, MacKillop N, Rovati L, Serni U, et al. Recommendations for the registration of drugs used in the treatment of osteoarthritis: an update on biochemical markers. Osteoarthritis Cartilage. 2001 May;9(4):289–293. [PubMed]
  • Garnero P, Rousseau JC, Delmas PD. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum. 2000 May;43(5):953–968. [PubMed]
  • Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, Rosenquist C, Qvist P. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone. 2001 Sep;29(3):209–215. [PubMed]
  • Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis. 2001 Jun;60(6):619–626. [PMC free article] [PubMed]
  • Garnero Patrick, Gineyts Evelyne, Christgau Stephan, Finck Barbara, Delmas Pierre D. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum. 2002 Jan;46(1):21–30. [PubMed]
  • Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, Christiansen C. Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem. 1998 Nov;44(11):2281–2289. [PubMed]
  • Rosenquist C, Qvist P, Bjarnason N, Christiansen C. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem. 1995 Oct;41(10):1439–1445. [PubMed]
  • Billinghurst RC, Wu W, Ionescu M, Reiner A, Dahlberg L, Chen J, van Wart H, Poole AR. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase. Arthritis Rheum. 2000 Mar;43(3):664–672. [PubMed]
  • Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000;11 (Suppl 6):S2–17. [PubMed]
  • Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996 Mar;11(3):337–349. [PubMed]
  • van Saase JL, van Romunde LK, Cats A, Vandenbroucke JP, Valkenburg HA. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis. 1989 Apr;48(4):271–280. [PMC free article] [PubMed]
  • Chaisson CE, Zhang Y, McAlindon TE, Hannan MT, Aliabadi P, Naimark A, Levy D, Felson DT. Radiographic hand osteoarthritis: incidence, patterns, and influence of pre-existing disease in a population based sample. J Rheumatol. 1997 Jul;24(7):1337–1343. [PubMed]
  • Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 1998 Aug;41(8):1343–1355. [PubMed]
  • Felson DT, Nevitt MC. Estrogen and osteoarthritis: how do we explain conflicting study results? Prev Med. 1999 May;28(5):445–450. [PubMed]
  • Felson DT, Nevitt MC. The effects of estrogen on osteoarthritis. Curr Opin Rheumatol. 1998 May;10(3):269–272. [PubMed]
  • Nevitt MC, Felson DT. Sex hormones and the risk of osteoarthritis in women: epidemiological evidence. Ann Rheum Dis. 1996 Sep;55(9):673–676. [PMC free article] [PubMed]
  • Nevitt MC, Cummings SR, Lane NE, Hochberg MC, Scott JC, Pressman AR, Genant HK, Cauley JA. Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Study of Osteoporotic Fractures Research Group. Arch Intern Med. 1996 Oct 14;156(18):2073–2080. [PubMed]
  • Felson DT, Chaisson CE. Understanding the relationship between body weight and osteoarthritis. Baillieres Clin Rheumatol. 1997 Nov;11(4):671–681. [PubMed]
  • Hart DJ, Spector TD. The relationship of obesity, fat distribution and osteoarthritis in women in the general population: the Chingford Study. J Rheumatol. 1993 Feb;20(2):331–335. [PubMed]
  • Manninen P, Riihimäki H, Heliövaara M, Mäkelä P. Overweight, gender and knee osteoarthritis. Int J Obes Relat Metab Disord. 1996 Jun;20(6):595–597. [PubMed]

Figures and Tables

Figure 1
Age dependent variations in (A) creatinine corrected urinary CTX-II; (B) creatinine corrected urinary CTX-I; and (C) serum osteocalcin concentrations in women (open circle) and men (filled circle) aged 20–87. Results shown are means (SEM). Table ...
Figure 2
Influence of age and menopausal status on creatinine corrected urinary CTX-II concentrations in women. (A) A scatterplot presenting individual values of premenopausal (filled circle) and postmenopausal (open circle) women. (B) Influence of menopausal ...
Figure 3
(A) Influence of HRT on creatinine corrected urinary CTX-II concentrations independently of age and BMI. (B) Creatinine corrected urinary CTX-II concentrations in women having received HRT for 0–4 years and 4–10 years, respectively. Results ...
Figure 4
Influence of BMI on creatinine corrected urinary CTX-II concentrations in subjects older than 35 years of age. Results are adjusted for age and shown as mean with SEM. *p<0.001.

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...